- Home
- MYGN vs PCRX Comparison
MYGN vs PCRX Comparison
Compare MYGN & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- PCRX
- Stock Information
- Founded
- MYGN 1991
- PCRX 2006
- Country
- MYGN United States
- PCRX United States
- Employees
- MYGN N/A
- PCRX N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- MYGN Health Care
- PCRX Health Care
- Exchange
- MYGN Nasdaq
- PCRX Nasdaq
- Market Cap
- MYGN 1.2B
- PCRX 1.2B
- IPO Year
- MYGN 1995
- PCRX 2011
- Fundamental
- Price
- MYGN $14.18
- PCRX $25.16
- Analyst Decision
- MYGN Hold
- PCRX Buy
- Analyst Count
- MYGN 13
- PCRX 9
- Target Price
- MYGN $22.54
- PCRX $26.22
- AVG Volume (30 Days)
- MYGN 1.2M
- PCRX 786.1K
- Earning Date
- MYGN 02-24-2025
- PCRX 02-27-2025
- Dividend Yield
- MYGN N/A
- PCRX N/A
- EPS Growth
- MYGN N/A
- PCRX N/A
- EPS
- MYGN N/A
- PCRX N/A
- Revenue
- MYGN $823,600,000.00
- PCRX $694,957,000.00
- Revenue This Year
- MYGN $13.60
- PCRX $5.55
- Revenue Next Year
- MYGN $3.25
- PCRX $5.64
- P/E Ratio
- MYGN N/A
- PCRX N/A
- Revenue Growth
- MYGN 12.15
- PCRX 4.40
- 52 Week Low
- MYGN $12.04
- PCRX $11.16
- 52 Week High
- MYGN $29.30
- PCRX $31.67
- Technical
- Relative Strength Index (RSI)
- MYGN 55.82
- PCRX 52.48
- Support Level
- MYGN $14.13
- PCRX $25.41
- Resistance Level
- MYGN $15.47
- PCRX $26.89
- Average True Range (ATR)
- MYGN 0.72
- PCRX 1.18
- MACD
- MYGN 0.27
- PCRX -0.36
- Stochastic Oscillator
- MYGN 61.38
- PCRX 4.35
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.